SCHEMBL23914731

SCHEMBL23914731

COC(=O)/C=C1\OC(=O)c2ccccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.55
HPGD P15428 4/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
LMNA P02545 2/20 0.55
MAPT P10636 1/20 0.55
TSHR P16473 1/20 0.51
MAPK1 P28482 1/20 0.51
KDM4E B2RXH2 4/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C19 P33261 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
TRPA1 O75762 1/20 0.49
POLB P06746 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23909086 0.81 ALDH1A1 (0.47) ALDH1A1HPGDMEN1KMT2ALMNA
SCHEMBL13775156 0.81 ALDH1A1 (0.56) ALDH1A1HPGDMEN1KMT2ALMNA
SCHEMBL23915344 0.81 ALDH1A1 (0.47) ALDH1A1HPGDMEN1KMT2ALMNA
SCHEMBL23909087 0.81 ALDH1A1 (0.47) ALDH1A1HPGDMEN1KMT2ALMNA
SCHEMBL9234683 0.81 ALDH1A1 (0.56) ALDH1A1HPGDMEN1KMT2ALMNA
SCHEMBL5009486 0.81 ALDH1A1 (0.56) ALDH1A1HPGDMEN1KMT2ALMNA
Phthalic Anhydride SCHEMBL27702350 0.79 TDP1 (0.50) ALDH1A1HPGDMEN1KMT2ALMNA
SCHEMBL8767253 0.77 ALDH1A1 (0.60) ALDH1A1HPGDMEN1KMT2ALMNA
SCHEMBL17293790 0.77 ALDH1A1 (0.60) ALDH1A1HPGDMEN1KMT2ALMNA
SCHEMBL8767247 0.77 ALDH1A1 (0.60) ALDH1A1HPGDMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3649119-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GALAPAGOS NV (BE) 2021-11-03 EP disclosed
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS GILEAD SCIENCES, INC. 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210315893-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS S1PR1, S1PR3, S1PR2 ALDH1A1 944/4885HPGD 2060/4885MEN1 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.